|
**Overview**: EGFR Mutational Analysis Panel**Introduction**: The EGFR Mutational Analysis Panel is a diagnostic tool designed to detect EGFR mutations using FFPE tissue samples. In India, EGFR mutations drive ~40 percent of NSCLC adenocarcinomas, with exon 19 deletions and exon 21 L858R most common and highly responsive to TKIs. High morbidity from under-testing in rural/low-SES lung cancer patients, limited NGS access, delayed targeted therapy leading to chemotherapy resistance or progression. Per oncology practices aligned with ICMR and Indian Society of Medical Oncology guidelines, the test employs NGS for exons 18-21 over 1-2 days with high sensitivity/specificity, valuable for precision oncology. This diagnostic falls under cancer mutation screening and targets NSCLC patients (especially non-smokers/females), addressing accurate detection to guide first-line TKI or combination therapy. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise treatment selection and improving survival. Its FFPE-based approach ensures reliable tumor mutation analysis.**Other Names**: EGFR Analysis Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/oncology, compliant with 2025 standards.**Historical Milestone**: EGFR exon-focused testing; in India, standard in lung cancer centers.**Purpose**: The test detects 4 parameters including EGFR Exon 18 to guide mutation analysis, identify actionable variants, inform targeted therapy.**Test Parameters**: 1. EGFR Exon 18, 2. Exon 19, 3. Exon 20, 4. Exon 21.**Pretest Condition**: No fasting required; patients should have confirmed NSCLC diagnosis with FFPE tissue.**Specimen**: FFPE tissue block (0.5-2 cm³), transported within specified times to maintain sample viability.Sample Stability: Indefinite when properly stored (paraffin-embedded blocks stable long-term).**Medical History**: Patients should provide details on cancer histology, stage, smoking status, prior therapy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated mutations including poor response, benefits of profiling, and minimal discomfort (tissue already collected).**Procedural Considerations**: The test involves sample processing using NGS by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Poor tissue quality, low tumor content, or delays can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Actionable EGFR mutations indicate TKI benefit, necessitating specialist input. No mutations may require follow-up.**Specialist Consultation**: Medical oncologists should be consulted for management.**Additional Supporting Tests**: Liquid biopsy or IHC for confirmation.**Test Limitations**: Covers hotspots only; comprehensive approach required.**References**: Indian Journal of Medical Oncology 2024, EGFR Studies India 2023. |
